Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × tucatinib × Breast × Clear all

Phase

Phase 2 15 Phase 1/2 8 Phase 1 8 Phase 3 2 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1 Breast 1

Conditions

HER2-positive Breast Cancer 1

Interventions

Capecitabine 16 Paclitaxel 15 Docetaxel 13 Cyclophosphamide 11 Carboplatin 11 Epirubicin 9 Trastuzumab 8 Letrozole 8 Gemcitabine 8 Doxorubicin 7 pertuzumab 5 Vinorelbine 4 Cisplatin 4 130-nm albumin-bound paclitaxel 4 exemestane 3 Tamoxifen 3 Lapatinib 3 AC protocol 3 pyrotinib 2 palbociclib 2 camrelizumab 2 Zoledronic Acid 2 Thiotepa 2 Taxes 2 Neoadjuvant Therapy 2 Melatonin 2 Goserelin 2 Fulvestrant 2 Fluorouracil 2 Exercise 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡